Collegium Pharmaceutical, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shareholders voted on company leadership and how much executives earn, showing investor confidence.
Company spent a huge sum to buy a new medicine, betting it will make more money and grow the business.
Investors learn how much money the company made and spent in the first three months of the year.
An experienced finance expert from Ernst & Young joins leadership to guide the company's decisions.
A long-time leader steps down as part of planned board refreshment and succession planning.
Company committed to a major purchase of an ADHD medicine to expand its product lineup.
Investors see the complete yearly results showing total revenue, costs, and profit for 2025.
Stocky reads Collegium Pharmaceutical, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Collegium Pharmaceutical, Inc.'s most recent tracked filing was a 8-K on 15 May 2026: Eight directors elected; exec pay approved by shareholders.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.